Cargando…
Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting
BACKGROUND: Lung cancer (LC) chemotherapy results in several adverse events (AEs). Data regarding supportive care medications (SCMs) offered to prevent/treat AEs in resource-limited settings are lacking. A prospective observational study was carried out to find the effectiveness of SCMs in real-life...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330793/ https://www.ncbi.nlm.nih.gov/pubmed/30604703 http://dx.doi.org/10.4103/lungindia.lungindia_321_17 |
_version_ | 1783387035443134464 |
---|---|
author | Muthu, Valliappan Mylliemngap, Badari Prasad, Kuruswamy Thurai Behera, Digambar Singh, Navneet |
author_facet | Muthu, Valliappan Mylliemngap, Badari Prasad, Kuruswamy Thurai Behera, Digambar Singh, Navneet |
author_sort | Muthu, Valliappan |
collection | PubMed |
description | BACKGROUND: Lung cancer (LC) chemotherapy results in several adverse events (AEs). Data regarding supportive care medications (SCMs) offered to prevent/treat AEs in resource-limited settings are lacking. A prospective observational study was carried out to find the effectiveness of SCMs in real-life setting. METHODS: Newly diagnosed LC patients receiving first-line chemotherapy at a tertiary referral center in North India (from July 2014 to September 2015) were enrolled. Incidence, timing of onset, duration, and grades of chemotherapy-related AEs were recorded. We assessed compliance to mandatory SCMs using a structured questionnaire. Patients also recorded various symptoms, frequency of need-based SCMs, visits to local practitioners, and hospitalization (if any) during the intercycle period. RESULTS: Of the 112 patients enrolled, majority were males (83.9%, n = 94), current/ex-smokers (82.1%, n = 92), had advanced stage (Stage IIIB = 33.9% [n = 38] and Stage IV = 46.4% [n = 52]), and were non-small cell lung cancer (72.3%, n = 81). AEs were reported in 566 cycles (94%) out of a total of 602 chemotherapy cycles. Diarrhea was the most common AE (180 cycles, 29.9%) developing after a mean (standard deviation) duration of 3.6 (2.5) days and lasting for 4 (3.3) days. Vomiting (138 cycles, 22.9%) and constipation (121 cycles, 20.1%) were other common AEs. Grade 3/4 AEs occurred in 6.9% (39/566) cycles. Need-based SCMs were required in 479 of the 566 cycles (84.6%). Proportion of patients with Grade 3/4 AEs and hospitalization was highest for mucositis (16.1% Grade 3/4 and 9.7% hospitalized); followed by vomiting (10.1% Grade 3/4 and 8.7% hospitalized). Anemia was seen in 441 of 602 chemotherapy cycles (73.3%). Frequency and severity of anemia continued to increase with each chemotherapy cycle. CONCLUSION: LC chemotherapy has a high prevalence of AEs. However, the majority are low grade recovering with need-based SCMs, without any need for hospitalization. |
format | Online Article Text |
id | pubmed-6330793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-63307932019-04-17 Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting Muthu, Valliappan Mylliemngap, Badari Prasad, Kuruswamy Thurai Behera, Digambar Singh, Navneet Lung India Original Article BACKGROUND: Lung cancer (LC) chemotherapy results in several adverse events (AEs). Data regarding supportive care medications (SCMs) offered to prevent/treat AEs in resource-limited settings are lacking. A prospective observational study was carried out to find the effectiveness of SCMs in real-life setting. METHODS: Newly diagnosed LC patients receiving first-line chemotherapy at a tertiary referral center in North India (from July 2014 to September 2015) were enrolled. Incidence, timing of onset, duration, and grades of chemotherapy-related AEs were recorded. We assessed compliance to mandatory SCMs using a structured questionnaire. Patients also recorded various symptoms, frequency of need-based SCMs, visits to local practitioners, and hospitalization (if any) during the intercycle period. RESULTS: Of the 112 patients enrolled, majority were males (83.9%, n = 94), current/ex-smokers (82.1%, n = 92), had advanced stage (Stage IIIB = 33.9% [n = 38] and Stage IV = 46.4% [n = 52]), and were non-small cell lung cancer (72.3%, n = 81). AEs were reported in 566 cycles (94%) out of a total of 602 chemotherapy cycles. Diarrhea was the most common AE (180 cycles, 29.9%) developing after a mean (standard deviation) duration of 3.6 (2.5) days and lasting for 4 (3.3) days. Vomiting (138 cycles, 22.9%) and constipation (121 cycles, 20.1%) were other common AEs. Grade 3/4 AEs occurred in 6.9% (39/566) cycles. Need-based SCMs were required in 479 of the 566 cycles (84.6%). Proportion of patients with Grade 3/4 AEs and hospitalization was highest for mucositis (16.1% Grade 3/4 and 9.7% hospitalized); followed by vomiting (10.1% Grade 3/4 and 8.7% hospitalized). Anemia was seen in 441 of 602 chemotherapy cycles (73.3%). Frequency and severity of anemia continued to increase with each chemotherapy cycle. CONCLUSION: LC chemotherapy has a high prevalence of AEs. However, the majority are low grade recovering with need-based SCMs, without any need for hospitalization. Medknow Publications & Media Pvt Ltd 2019 /pmc/articles/PMC6330793/ /pubmed/30604703 http://dx.doi.org/10.4103/lungindia.lungindia_321_17 Text en Copyright: © 2018 Indian Chest Society http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Muthu, Valliappan Mylliemngap, Badari Prasad, Kuruswamy Thurai Behera, Digambar Singh, Navneet Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting |
title | Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting |
title_full | Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting |
title_fullStr | Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting |
title_full_unstemmed | Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting |
title_short | Adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting |
title_sort | adverse effects observed in lung cancer patients undergoing first-line chemotherapy and effectiveness of supportive care drugs in a resource-limited setting |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330793/ https://www.ncbi.nlm.nih.gov/pubmed/30604703 http://dx.doi.org/10.4103/lungindia.lungindia_321_17 |
work_keys_str_mv | AT muthuvalliappan adverseeffectsobservedinlungcancerpatientsundergoingfirstlinechemotherapyandeffectivenessofsupportivecaredrugsinaresourcelimitedsetting AT mylliemngapbadari adverseeffectsobservedinlungcancerpatientsundergoingfirstlinechemotherapyandeffectivenessofsupportivecaredrugsinaresourcelimitedsetting AT prasadkuruswamythurai adverseeffectsobservedinlungcancerpatientsundergoingfirstlinechemotherapyandeffectivenessofsupportivecaredrugsinaresourcelimitedsetting AT beheradigambar adverseeffectsobservedinlungcancerpatientsundergoingfirstlinechemotherapyandeffectivenessofsupportivecaredrugsinaresourcelimitedsetting AT singhnavneet adverseeffectsobservedinlungcancerpatientsundergoingfirstlinechemotherapyandeffectivenessofsupportivecaredrugsinaresourcelimitedsetting |